Eisai R&D Management Co. Ltd., National Institutes for Quantum and Radiological Science and Technology (QST), Ono Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Co. Ltd. have patented new radiolabeled compounds targeting α-synuclein (α-Syn, SNCA) and acting as optical imaging agents for the diagnosis of Lewy body dementia (DLB), multiple system atrophy and Parkinson’s disease.

Di-cyclopropyl based interleukin-17A (IL-17A) production inhibitors have been reported in a Dice Alpha Inc. patent as potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.

Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic obstructive pulmonary disease, fibrosis, psoriasis, erectile dysfunction, multiple sclerosis, heart failure, overactive bladder and neuropathic pain, among others.

Researchers at the University of Bonn and Westfälische Wilhelms-Universiteit Münster have prepared labeled compounds acting as 5’-nucleotidase (CD73) inhibitors.

Sanofi SA has identified thienopyrrolotriazine compounds reported to be useful for the treatment of multiple system atrophy, frontotemporal dementia, multiple sclerosis, amyotrophic lateral sclerosis, brain injury, Alzheimer’s and Parkinson’s disease.

Amgen Inc. has patented new quinazoline compounds acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.

Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed stimulator of interferon genes protein (STING; TMEM173) modulators reported to be useful for the treatment of cancer, infections and autoimmune disease.

Research at MUSC Foundation for Research Development has led to the identification of small molecules targeting the voltage-dependent anion channel (VDAC) NADH binding pocket.

Nanomedsyn has described lysosome targeting chimeras (LYTACs) comprising cation-independent mannose-6-phosphate receptor (IGF-2R)-targeting glycosides covalently linked to TNF-α degradation inducers.